Zacks Investment Research cut shares of ABCAM PLC/ADR (OTCMKTS:ABCZY) from a hold rating to a sell rating in a report published on Thursday morning.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Separately, ValuEngine cut ABCAM PLC/ADR from a buy rating to a hold rating in a research note on Friday, December 21st.
Shares of ABCZY traded up $0.96 during mid-day trading on Thursday, hitting $16.28. 974 shares of the company’s stock traded hands, compared to its average volume of 15,303. ABCAM PLC/ADR has a 1 year low of $12.52 and a 1 year high of $20.29.
ABCAM PLC/ADR Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABCAM PLC/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABCAM PLC/ADR and related companies with MarketBeat.com's FREE daily email newsletter.